E Fund Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $497K | Buy |
8,990
+4,853
| +117% | +$268K | 0.02% | 227 |
|
|
2025
Q1 | $200K | Sell |
4,137
-71,950
| -95% | -$3.48M | 0.01% | 362 |
|
|
2024
Q4 | $2.94M | Buy |
76,087
+4,421
| +6% | +$171K | 0.15% | 84 |
|
|
2024
Q3 | $3.22M | Buy |
+71,666
| New | +$3.22M | 0.17% | 65 |
|
|
2024
Q2 | – | Sell |
-11,304
| Closed | -$327K | – | 360 |
|
|
2024
Q1 | $327K | Buy |
11,304
+2,347
| +26% | +$67.9K | 0.02% | 267 |
|
|
2023
Q4 | $205K | Sell |
8,957
-9,034
| -50% | -$207K | 0.01% | 279 |
|
|
2023
Q3 | $300K | Buy |
17,991
+2,637
| +17% | +$44K | 0.02% | 210 |
|
|
2023
Q2 | $424K | Buy |
15,354
+6,641
| +76% | +$183K | 0.03% | 153 |
|
|
2023
Q1 | $200K | Sell |
8,713
-6,769
| -44% | -$155K | 0.01% | 302 |
|
|
2022
Q4 | $169K | Sell |
15,482
-8,366
| -35% | -$91.3K | 0.01% | 309 |
|
|
2022
Q3 | $201K | Sell |
23,848
-12,185
| -34% | -$103K | 0.02% | 305 |
|
|
2022
Q2 | $285K | Buy |
36,033
+25,593
| +245% | +$202K | 0.03% | 243 |
|
|
2022
Q1 | $247K | Buy |
+10,440
| New | +$247K | 0.01% | 259 |
|